Mednet Logo

What leads you to consider prescribing a nasal spray formulation for the treatment of acute migraine?

Community PollStarted

What percentage of your patients receive a nonoral acute treatment for migraine? This includes triptan, gepant, DHE, lidocaine, and ketamine nasal sprays.

30 physicians have voted

Join Mednetto vote and see how they answered.

5 Answers
Mednet Member
Mednet MemberInvited Expert
Neurology · Albert Einstein College of Medicine
Answered on

Interesting discussion. From my perspective, one of the big choices in the acute treatment of migraine is whether to give an oral or non-oral treatment. Patient preference studies show that oral agents are preferred if they work so I usually start there. Most patients prefer nasal sprays to subcutan...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Neurology · UCLA
Answered on

I completely agree with the reasons posted by Dr. @Dr. First Last. I usually agree with my longtime friend, Dr. @Dr. First Last; but I have to say that I disagree with him this time.

Certain nasal sprays work more quickly than comparable tablets, such as Zomig nasal spray, which was my favorite way ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Neurology · Barrow Neurological Institute
Answered on

Major reasons to consider are:

  • Faster onset of action.
  • Patients with significant nausea/vomiting who cannot tolerate oral.
  • Patients with gastroparesis (due to migraine or other causes) lead to poor absorption of oral medications.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Neurology · Greater Boston Headache Center at Boston Advanced Medicine
Answered on

I never prescribe nasal sprays for the abortive treatment of migraine because I am not convinced that any of them are more effective than the corresponding tablets (sumatriptan and zolmitriptan) or similar medications in tablet form (gepants).

I have extensive experience with the liquid dihydroergot...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Neurology · Stanford University
Answered on

The only thing I would add to this excellent discussion is the elephant in the room: payors and their restrictive policies regarding access. For many providers, the prospect of prior authorizations and peer-to-peer is daunting and prohibitive in small practices. Until we face this challenge head-on,...

Join for free or sign in to see the full answer